Impact of CD19 CAR T-Cell Therapy on Pathogen-Specific Antibody Titers in Lymphoma Patients
{{output}}
Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy has exhibited efficacy in treating relapsed/refractory high-grade B-cell malignancies, but off-tumor effects cause prolonged hypogammaglobulinemia and B-cel... ...
